Press Releases

May 13, 2024
STOUGHTON, Mass. , May 13, 2024 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions, today announced that it has entered into an Accelerated Share
May 9, 2024
– Generated Q1’24 Net Revenue of $144.9 Million – – Delivered Q1’24 Record Belbuca ® Revenue of $50.7 Million ; Total Prescriptions Up 4.2% Year-over-Year – – Achieved Q1’24 GAAP Net Income of $27.7 Million vs. Q1’23 GAAP Net Loss of $(17.4) Million – – Delivered Q1’24 Adjusted EBITDA of $92.4
May 9, 2024
– Joe Ciaffoni to Step Down as President and Chief Executive Officer – – Board Chairman Michael Heffernan to Serve as Interim President and Chief Executive Officer – – Board of Directors has Initiated the Search for a Successor – STOUGHTON, Mass. , May 09, 2024 (GLOBE NEWSWIRE) -- Collegium
April 25, 2024
STOUGHTON, Mass. , April 25, 2024 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc.  (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions, today announced that it will report first quarter 2024
April 3, 2024
STOUGHTON, Mass. , April 03, 2024 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc.  (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions, today announced that management will participate in a
February 22, 2024
– Generated Record Quarterly and Full-Year Net Revenue of $149.7 Million and $566.8 Million – – Achieved Quarterly and Full-Year GAAP Net Income of $31.9 Million and $48.2 Million – – Delivered Record Quarterly and Full-Year Adjusted EBITDA of $104.2 Million and $367.0 Million – – Ended 2023 with
January 3, 2024
– Product Revenues, Net Expected in the Range of $580.0 Million to $595.0 Million – – Adjusted Operating Expenses* Expected in the Range of $120.0 Million to $125.0 Million – – Adjusted EBITDA* Expected in the Range of $380.0 Million to $395.0 Million – – $150.0 Million Share Repurchase Program